AGT

Across TCGA pan-cancer cohorts, AGT Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AGT data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher AGT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGT expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

KIRC, SKCM, and LUSC are the cancer types where AGT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.123	0.805	<.001	42	view →
SKCM	DFS	Median	III,IV	1.000	0.567	.007	14	view →
LUSC	OS	Median	II,III,IV	0.080	0.743	<.001	12	view →
HNSC	DFS	Median	All	0.171	0.626	.020	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.463	0.837	.001	4	view →
COAD	OS	Median	II,III,IV	0.176	0.655	.016	2	view →
UCEC	DFS	Median	II,III,IV	0.904	0.438	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AGT–KIRC (OS)

Open the KIRC breakdown →